The clinical impact of aluminium overload in renal failure

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 2, 2002, Pages 9-12

  Cannata Andía, Jorge B ^a   Fernández Martín, Jose L ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Aluminium; Bone remodelling; Desferrioxamine; Phosphate binders

Indexed keywords

ALUMINUM; DIALYSIS FLUID; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; SEVELAMER;

ARTICLE; BIOACCUMULATION; BONE BIOPSY; BONE REMODELING; BRAIN; CALCIUM HOMEOSTASIS; CHELATION THERAPY; CHRONIC TOXICITY; CONTROLLED STUDY; DIALYSATE; DRUG CONTAMINATION; HEAVY METAL POISONING; HEMATOPOIESIS; HORMONE SYNTHESIS; HUMAN; KIDNEY FAILURE; LONG TERM EXPOSURE; METABOLIC BONE DISEASE; OSSIFICATION; OSTEOLYSIS; PREVALENCE; PRIORITY JOURNAL;

EID: 0036224171     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_2.9     Document Type: Article

References (45)

1. The dialysis encephalopathy syndrome. Possible aluminum intoxication
2. Aluminum metabolism and toxicity in uremia
3. Aspects of aluminum toxicity
4. Hyperaluminaemia from aluminum resins in renal failure
5. Aluminium toxicity in rats
6. Letter: The myth of aluminum toxicity
7. Osteomalacic dialysis osteodystrophy: Evidence for a waterborne aetiological agent, probably aluminium
8. Dialysis osteomalacia and aluminum intoxication
9. Fracturing dialysis osteodystrophy and dialysis encephalopathy. An epidemiological survey
10. Epidemiology of renal osteodystrophy in Iberoamerica
11. Prevention of aluminium exposure through dialysis fluids. Analysis of changes in the last 8 years
12. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis
13. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure
14. Systemic aluminum toxicity: Effects on bone, hematopoietic tissue, and kidney
15. Aluminium-induced bone disease in uremic rats: Effect of deferoxamine
16. Aluminum and renal osteodystrophy
17. The parathyroid gland and aluminum overload: An overview
18. Effect of aluminium load on parathyroid hormone synthesis
19. Effect of aluminium on the development of hyperparathyroidism and bone disease in the azotaemic rat
20. Effect of acute aluminium overload on calcium and parathyroid-hormone metabolism
21. Influence of aluminium hydroxide intake on haemoglobin concentrations and blood transfusion requirements in haemodialysis patients
22. Insights into the complex aluminium and iron relationship
23. Iron uptake in aluminium overload: In vivo and in vitro studies
24. Role of iron metabolism in absorption and cellular uptake of aluminum
25. The influence of aluminium on parathyroid hormone levels in haemodialysis patients
26. Aluminium intoxication in the rat induces partial resistance to the effect of recombinant human erythropoietin
27. Mechanisms of aluminum-induced microcytosis: Lessons from accidental aluminum intoxication
28. Resistance to recombinant human erythropoietin in hemodialysis patients
29. Brain-aluminium concentration in dialysis encephalopathy
30. Aluminum induced oxidative events and its relation to inflammation: A role for the metal in Alzheimer's disease
31. Differential toxicity of aluminum salts in human cell lines of neural origin: Implications for neurodegeneration
32. Encephalopathy after bladder irrigation with alum: Case report and literature review
33. Aluminum toxicity in undialyzed patients with chronic renal failure
34. The role of experimental chronic renal failure and aluminium intoxication in cellular immune response
35. Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients
36. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload
37. Diagnosis and treatment of aluminium bone disease
38. Influence of iron status in the response to the deferoxamine test
39. Reconsidering the importance of long-term low-level aluminum exposure in renal failure patients
40. Ultrafiltrable aluminium after very low doses of desferrioxamine
41. Treatment of aluminium intoxication: A new scheme for desferrioxamine administration
42. Sevelamer is more effective at controlling disorders of mineral metabolism than calcium-based phosphate binders in hemodialysis patients
43. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients
44. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients
45. An assessment of the effects of lanthanum on bone in a chronic renal failure (CRF) rat model